Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azeliragon to Decrease Chemotherapy-Related Cardiotoxicity in Early Breast Cancer
NCT05256745Phase 2Recruiting
- Sponsor
- Georgetown University
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azeliragon in Cardiotoxicity, No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity., sponsored by Georgetown University. Started Jun 2023; status: recruiting.
02
Drugs
azeliragon
03
Conditions
CardiotoxicityNo canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT05256745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256745.